| |
| |
|
| Insider
Information: |
Pops Richard F |
| Relationship: |
Director |
| City: |
Cambridge |
| State: |
MA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
4 |
|
| Direct
Shares |
1,301,687 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$39,025,291 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
1,301,687 |
|
|
| Total
Value |
$39,025,291 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Neurocrine Biosciences Inc |
NBIX |
Director |
2024-03-13 |
29,512 |
2005-11-23 |
0 |
Premium* |
|
|
Alkermes Plc |
ALKS |
Director and CEO, Alke... |
2024-02-08 |
1,179,675 |
2011-09-16 |
0 |
Premium* |
|
|
Epizyme, Inc. |
EPZM |
Director |
2013-05-30 |
60,000 |
|
0 |
Premium* |
|
|
Acceleron Pharma Inc |
XLRN |
Director |
2019-01-25 |
32,500 |
|
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| NBIX |
Neurocrine Biosciences In... |
Director |
– • – |
2024-03-13 |
4 |
AS |
$140.33 |
$3,255,621 |
D/D |
(23,200) |
29,512 |
0 |
% |
|
| NBIX |
Neurocrine Biosciences In... |
Director |
– • – |
2024-03-13 |
4 |
OE |
$42.76 |
$992,032 |
D/D |
23,200 |
52,712 |
0 |
- |
|
| NBIX |
Neurocrine Biosciences In... |
Director |
– • – |
2024-03-11 |
4 |
AS |
$140.00 |
$14,000 |
D/D |
(100) |
29,512 |
0 |
% |
|
| NBIX |
Neurocrine Biosciences In... |
Director |
– • – |
2024-03-11 |
4 |
OE |
$42.76 |
$4,276 |
D/D |
100 |
29,612 |
0 |
- |
|
| NBIX |
Neurocrine Biosciences In... |
Director |
– • – |
2024-03-08 |
4 |
AS |
$140.05 |
$238,078 |
D/D |
(1,700) |
29,512 |
0 |
% |
|
| NBIX |
Neurocrine Biosciences In... |
Director |
– • – |
2024-03-08 |
4 |
OE |
$42.76 |
$72,692 |
D/D |
1,700 |
31,212 |
0 |
- |
|
| NBIX |
Neurocrine Biosciences In... |
Director |
– • – |
2024-02-20 |
4 |
OE |
$12.98 |
$194,700 |
D/D |
15,000 |
44,512 |
0 |
- |
|
| NBIX |
Neurocrine Biosciences In... |
Director |
– • – |
2024-02-20 |
4 |
AS |
$132.47 |
$1,987,047 |
D/D |
(15,000) |
29,512 |
0 |
% |
|
| ALKS |
Alkermes Plc |
Director and CEO, Alkermes plc |
• • – |
2024-02-08 |
4 |
D |
$26.77 |
$2,456,335 |
D/D |
(91,757) |
1,179,675 |
0 |
- |
|
| ALKS |
Alkermes Plc |
Director and CEO, Alkermes plc |
• • – |
2024-02-08 |
4 |
A |
$0.00 |
$0 |
D/D |
218,551 |
1,271,432 |
0 |
- |
|
| ALKS |
Alkermes Plc |
Director and CEO, Alkermes plc |
• • – |
2023-02-21 |
4 |
D |
$27.77 |
$399,499 |
D/D |
(14,386) |
1,052,881 |
0 |
- |
|
| ALKS |
Alkermes Plc |
Director and CEO, Alkermes plc |
• • – |
2023-02-21 |
4 |
OE |
$0.00 |
$0 |
D/D |
32,400 |
1,067,267 |
0 |
- |
|
| ALKS |
Alkermes Plc |
Director and CEO, Alkermes plc |
• • – |
2023-02-20 |
4 |
D |
$28.07 |
$1,491,780 |
D/D |
(53,145) |
1,034,867 |
0 |
- |
|
| ALKS |
Alkermes Plc |
Director and CEO, Alkermes plc |
• • – |
2023-02-20 |
4 |
A |
$0.00 |
$0 |
D/D |
119,713 |
1,088,012 |
0 |
- |
|
| NBIX |
Neurocrine Biosciences In... |
Director |
– • – |
2023-01-03 |
4 |
OE |
$12.71 |
$190,650 |
D/D |
15,000 |
44,512 |
0 |
- |
|
| NBIX |
Neurocrine Biosciences In... |
Director |
– • – |
2023-01-03 |
4 |
AS |
$119.20 |
$1,788,045 |
D/D |
(15,000) |
29,512 |
0 |
% |
|
| NBIX |
Neurocrine Biosciences In... |
Director |
– • – |
2022-05-09 |
4 |
AS |
$76.29 |
$1,144,463 |
D/D |
(15,000) |
29,512 |
0 |
% |
|
| NBIX |
Neurocrine Biosciences In... |
Director |
– • – |
2022-05-09 |
4 |
OE |
$6.66 |
$99,900 |
D/D |
15,000 |
37,012 |
0 |
- |
|
| ALKS |
Alkermes Plc |
Director and CEO, Alkermes plc |
• • – |
2022-02-21 |
4 |
D |
$25.08 |
$360,801 |
D/D |
(14,386) |
865,556 |
0 |
- |
|
| ALKS |
Alkermes Plc |
Director and CEO, Alkermes plc |
• • – |
2022-02-21 |
4 |
OE |
$0.00 |
$0 |
D/D |
32,400 |
879,942 |
0 |
- |
|
| ALKS |
Alkermes Plc |
Director and CEO, Alkermes plc |
• • – |
2022-02-16 |
4 |
D |
$26.79 |
$215,338 |
D/D |
(8,038) |
847,542 |
0 |
- |
|
| ALKS |
Alkermes Plc |
Director and CEO, Alkermes plc |
• • – |
2022-02-16 |
4 |
OE |
$0.00 |
$0 |
D/D |
18,125 |
855,580 |
0 |
- |
|
| ALKS |
Alkermes Plc |
Director and CEO, Alkermes plc |
• • – |
2021-09-14 |
4 |
A |
$0.00 |
$0 |
D/D |
81,682 |
873,722 |
0 |
- |
|
| ALKS |
Alkermes Plc |
Director and CEO, Alkermes plc |
• • – |
2021-09-14 |
4 |
D |
$30.60 |
$1,109,770 |
D/D |
(36,267) |
837,455 |
0 |
- |
|
| ALKS |
Alkermes Plc |
Director and CEO, Alkermes plc |
• • – |
2021-05-18 |
4 |
AS |
$21.90 |
$3,285,405 |
D/D |
(150,000) |
792,040 |
0 |
% |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
